Nano Cap New Millennium Growth Fund L P Acquires Shares of 15,000 XOMA Royalty Corporation $XOMA

Nano Cap New Millennium Growth Fund L P acquired a new stake in XOMA Royalty Corporation (NASDAQ:XOMA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 15,000 shares of the biotechnology company’s stock, valued at approximately $399,000.

Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of XOMA Royalty by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after buying an additional 29,298 shares during the period. Opaleye Management Inc. raised its stake in shares of XOMA Royalty by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company’s stock worth $6,428,000 after buying an additional 2,044 shares during the period. Woodline Partners LP raised its stake in shares of XOMA Royalty by 16.5% during the 3rd quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock worth $8,091,000 after buying an additional 29,715 shares during the period. Geode Capital Management LLC raised its stake in shares of XOMA Royalty by 9.1% during the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock worth $5,132,000 after buying an additional 16,929 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of XOMA Royalty by 4.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock worth $1,124,000 after buying an additional 1,269 shares during the period. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Royalty Trading Down 0.4%

Shares of XOMA opened at $41.82 on Friday. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.96. The firm’s fifty day moving average is $36.10 and its two-hundred day moving average is $30.80. The stock has a market cap of $524.46 million, a PE ratio of 26.64 and a beta of 0.90. XOMA Royalty Corporation has a 52-week low of $22.29 and a 52-week high of $42.81.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. The company had revenue of $12.32 million during the quarter, compared to analysts’ expectations of $13.91 million. Research analysts forecast that XOMA Royalty Corporation will post 0.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

XOMA has been the subject of several research analyst reports. Lucid Cap Mkts downgraded XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. HC Wainwright lowered shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target on the stock. in a research note on Thursday, April 30th. Weiss Ratings lowered shares of XOMA Royalty from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Finally, Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $53.75.

XOMA Royalty Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.